Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMVPZBE)

• Drug Name: Iloprost Drug Info
• Synonyms: Ciloprost; Endoprost; Ilomedin; Ilomedine; Iloprostum; Ventavis; Iloprostum [Latin]; ZK 36374; E-1030; Iloprost (INN); Iloprost [BAN:INN]; SH-401; Ventavis (TN); ZK-36374; ZK-363775; [3H]-Iloprost; (16R,S)-Methyl-18,18,19,19-tetradehydro-6a-carbaprostaglandin I(sub 2); (5E)-5-[(3aS,4R,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxy-4-methyloct-1-en-6-ynyl]-3,3a,4,5,6,6a-hexahydro-1H-pentalen-2-ylidene]pentanoic acid; (5E)-5-[(3aS,5R,6aS)-5-hydroxy-4-[(1E,3S)-3-hydroxy-4-methyloct-1-en-6-yn-1-yl]hexahydropentalen-2(1H)-ylidene]pentanoic acid; (5E)-5-[(3aS,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxy-4-methyloct-1-en-6-ynyl]-3,3a,4,5,6,6a-hexahydro-1H-pentalen-2-ylidene]pentanoic acid; (5Z)-5-[(3aS,5R,6aS)-5-hydroxy-4-[(E,3R)-3-hydroxy-4-methyloct-1-en-6-ynyl]-3,3a,4,5,6,6a-hexahydro-1H-pentalen-2-ylidene]pentanoic acid; (E)-(3aS,4R,5R,6aS)-Hexahydro-5-hydroxy-4-((E)-(3S,4RS)-3-hydroxy-4-methyl-1-octen-6-ynyl)-delta(sup 2(1H),delta)-pentalenevaleric acid; (E)-5-(3aS,4R,5R,6aS)-5-Hydroxy-4((E)-(3S,4RS)-3-hydroxy-4-methyl-1-octen-6-inyl)perhydropentalen-2-yliden)valeriansaeure
• Therapeutic Class: Antihypertensive Agents
• Cross-matching ID:
  PubChem CID: 5311181
  ChEBI ID: CHEMBL494
  CAS Number: CAS 78919-13-8
  TTD Drug ID: D05ZTH
  VARIDT Drug ID: DR00099

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
Autoimmune thyroid disease	1.98	0.00e+0	46/53 (86.79%)	HLA-DQA1;CD86;HLA-C;...
Primary immunodeficiency	1.84	4.18e-2	33/38 (86.84%)	DCLRE1C;TAP1;IL7R;...
Kaposi sarcoma-associated herpesvirus infection	1.83	2.78e-2	172/193 (89.12%)	CXCL2;PPP3CA;BID;...
Type I diabetes mellitus	1.81	2.69e-2	38/43 (88.37%)	HLA-DQA1;CD86;HLA-C;...
Progesterone-mediated oocyte maturation	1.81	2.15e-2	75/100 (75%)	RPS6KA1;PLK1;CDK2;...
Human immunodeficiency virus 1 infection	1.81	1.99e-2	189/212 (89.15%)	PPP3CA;PRKCB;TAP1;...
Viral protein interaction with cytokine and cytokine re...	1.80	2.22e-2	84/100 (84%)	CXCL2;CXCL13;IL6;...
Aldosterone-regulated sodium reabsorption	1.79	2.09e-2	34/37 (91.89%)	PRKCB;ATP1A1;ATP1B3;...
Fanconi anemia pathway	1.78	1.99e-2	36/54 (66.67%)	FANCI;BRCA1;FANCG;...
Allograft rejection	1.77	1.91e-2	32/38 (84.21%)	HLA-DQA1;CD86;HLA-C;...
Nucleotide excision repair	1.77	1.84e-2	40/47 (85.11%)	POLE3;RAD23B;LIG1;...
Circadian entrainment	1.75	2.39e-2	85/97 (87.63%)	GUCY1A1;RPS6KA5;PRKCB;...
DNA replication	1.75	2.30e-2	34/36 (94.44%)	POLE3;LIG1;FEN1;...
Intestinal immune network for IgA production	1.72	2.81e-2	38/48 (79.17%)	IL6;HLA-DQA1;CD86;...
Glutamatergic synapse	1.70	3.66e-2	97/114 (85.09%)	SLC1A1;PPP3CA;PRKCB;...
Base excision repair	1.69	3.43e-2	29/33 (87.88%)	POLE3;LIG1;FEN1;...
Viral myocarditis	1.69	3.51e-2	53/60 (88.33%)	BID;HLA-DQA1;CD86;...
Cellular senescence	1.68	3.58e-2	139/156 (89.1%)	PPP3CA;CDK2;IL6;...
Human cytomegalovirus infection	1.68	3.58e-2	201/225 (89.33%)	PPP3CA;PRKCB;TAP1;...
Human T-cell leukemia virus 1 infection	1.67	3.82e-2	197/219 (89.95%)	PPP3CA;CDK2;IL6;...
Mineral absorption	1.66	3.92e-2	48/60 (80%)	MT1M;ATP1A1;MT1E;...
Regulation of lipolysis in adipocytes	1.65	4.07e-2	52/55 (94.55%)	FABP4;PDE3B;ADCY9;...
Herpes simplex virus 1 infection	1.63	4.83e-2	165/498 (33.13%)	TAP1;BID;BST2;...
Epstein-Barr virus infection	1.63	4.67e-2	189/202 (93.56%)	TAP1;RUNX3;CDK2;...
Antigen processing and presentation	1.63	4.49e-2	60/78 (76.92%)	LGMN;TAP1;CTSL;...
Cell cycle	1.63	4.45e-2	110/124 (88.71%)	PLK1;CDK2;TFDP1;...
Insulin resistance	1.63	4.42e-2	96/108 (88.89%)	RPS6KA1;TBC1D4;PRKCB;...
Hippo signaling pathway	1.62	4.30e-2	120/186 (64.52%)	AREG;BMP2;BMP7;...
Nicotinate and nicotinamide metabolism	-1.65	4.06e-2	25/35 (71.43%)	SIRT7;NT5C;NNT;...
Pentose and glucuronate interconversions	-1.71	2.17e-2	17/34 (50%)	UGT2B28;AKR1B1;UGDH;...
Oxidative phosphorylation	-1.72	1.74e-2	93/133 (69.92%)	NDUFB2;NDUFS2;ATP6V0E1;...
Glyoxylate and dicarboxylate metabolism	-1.73	1.62e-2	23/30 (76.67%)	AGXT;HYI;HAO1;...
Fatty acid degradation	-1.74	1.56e-2	40/43 (93.02%)	HADHB;ACAT1;CPT1A;...
Steroid hormone biosynthesis	-1.79	1.01e-2	43/61 (70.49%)	CYP2E1;UGT2B28;HSD17B6;...
Cholesterol metabolism	-1.85	8.67e-3	44/50 (88%)	ANGPTL3;LIPA;LIPC;...
Drug metabolism	-1.85	9.75e-3	78/151 (51.66%)	CYP2E1;UGT2B28;FMO3;...
Metabolism of xenobiotics by cytochrome P450	-1.85	1.00e-2	49/77 (63.64%)	CYP2E1;UGT2B28;EPHX1;...
Arginine biosynthesis	-1.90	2.60e-3	17/22 (77.27%)	GOT1;GLS;ARG1;...
Staphylococcus aureus infection	-1.96	1.56e-3	72/95 (75.79%)	C1QA;KRT14;CFH;...
Tyrosine metabolism	-2.00	0.00e+0	30/36 (83.33%)	DDC;ALDH3A1;MAOA;...
Steroid biosynthesis	-2.08	0.00e+0	19/20 (95%)	CYP24A1;CYP2R1;DHCR24;...
Retinol metabolism	-2.15	0.00e+0	41/68 (60.29%)	UGT2B28;CYP2W1;HSD17B6;...
Complement and coagulation cascades	-2.42	0.00e+0	76/85 (89.41%)	F12;SERPINF2;F10;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast

Breast adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF7	CVCL_0031	Homo sapiens	10uM	6H, 24H	Hide ▲

Colon

Colorectal adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HT-29	CVCL_0320	Homo sapiens	10uM	6H	Hide ▲

Hematopoietic system

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
ASC	CVCL_U602	Homo sapiens	10uM	24H	Show ▼

Kidney

Normal (Immortalized)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HA1E	CVCL_0284	Homo sapiens	10uM	6H	Show ▼

Normal (Transformed)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
1HAEo-	CVCL_0128	Homo sapiens	10uM	24H	Show ▼
NL20	CVCL_0461	Homo sapiens	10uM	24H	Show ▼

Liver

Hepatoblastoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
Hep G2	CVCL_0027	Homo sapiens	10uM	6H	Show ▼

Hepatocellular carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HuH-7	CVCL_0336	Homo sapiens	10uM	72H	Show ▼

Lung

Lung adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A549	CVCL_0023	Homo sapiens	10uM	6H, 24H	Show ▼

Non-small cell lung carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HCC515	CVCL_5134	Homo sapiens	10uM	6H	Show ▼

Normal (Fibroblast)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HFL1	CVCL_4295	Homo sapiens	10uM	24H	Show ▼
IMR-90	CVCL_0347	Homo sapiens	10uM	24H	Show ▼
WI-38	CVCL_0579	Homo sapiens	10uM	24H	Show ▼

Peripheral blood

Acute myeloid leukemia

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HL-60	CVCL_0002	Homo sapiens	0.37uM - 10uM	6H, 24H	Show ▼

Pleural effusion

Histiocytic lymphoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
U-937	CVCL_0007	Homo sapiens	0.37uM - 10uM	6H, 24H	Show ▼

Prostate

Prostate carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
PC-3	CVCL_0035	Homo sapiens	0.37uM - 10uM	6H, 24H	Show ▼
VCaP	CVCL_2235	Homo sapiens	10uM	6H, 24H	Show ▼

Skin

Melanoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A-375	CVCL_0132	Homo sapiens	10uM	6H	Show ▼